- Home
- / Bellerophon Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Bellerophon Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-29
Market Capitalization
$440.4 K
2024-10-29
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|---|---|---|
| General and administrative expense | 14.9M | 7.1M | 6.7M | 7.6M | 6.4M | 8.4M | 7.1M | 6.0M |
| Operating expense total | 48.2M | 23.8M | 24.6M | 27.9M | 17.5M | 26.3M | 22.4M | |
| EBIT | (46.6M) | (23.8M) | (24.6M) | (27.9M) | (17.5M) | (26.3M) | (20.2M) | (22.4M) |
| Interest income | 109.0K | 95.0K | 184.0K | 378.0K | 397.0K | |||
| Pre tax profit | (46.5M) | (24.3M) | (54.8M) | (2.6M) | (15.1M) | (26.9M) | (19.6M) | (22.2M) |
| Income tax expense | (438.0K) | (5.4M) | (1.8M) | (2.1M) | (1.8M) | (2.4M) | ||
| Net Income | (46.5M) | (23.8M) | (54.8M) | 2.8M | (13.3M) | (24.7M) | (17.8M) | (19.8M) |
| EPS | (2.1) |